166953-64-6

Basic information

• Product Name: BENZYL 4-BROMOTETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE
• Synonyms: N-CBZ-4-BROMO-PIPERIDINE;4-BROMO-N-Z-PIPERIDINE;BUTTPARK 93\50-52;BENZYL 4-BROMOTETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE;4-Bromopiperidine, N-CBZ protected;4-BROMO-N-Z-PIPERIDINE,96%;4-bromo-n-cbz piperidine;Benzyl 4-bromotetrahydro-1(2H)-pyridinecarboxylate, 90+%
• CAS NO: 166953-64-6
• Molecular Formula: C₁₃H₁₆BrNO₂
• Molecular Weight: 298.18
• Product Categories: API intermediates;C12 to C13;Building Blocks;C13;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;Piperidines
• Mol File: 166953-64-6.mol

Chemical Properties

• Boiling Point: 144 °C
• Flash Point: >230 °F
• Appearance: /
• Density: 1.374 g/mL at 25 °C(lit.)
• Vapor Pressure: 3.91E-06mmHg at 25°C
• Refractive Index: n20/D 1.5590(lit.)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -2.82±0.40(Predicted)
• CAS DataBase Reference: BENZYL 4-BROMOTETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL 4-BROMOTETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(166953-64-6)
• EPA Substance Registry System: BENZYL 4-BROMOTETRAHYDRO-1(2H)-PYRIDINECARBOXYLATE(166953-64-6)

Safety Data

• Hazard Codes: Xi
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• WGK Germany: 3
• Hazardous Substances Data: 166953-64-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H16BrNO2/c14-12-6-8-15(9-7-12)13(16)17-10-11-4-2-1-3-5-11/h1-5,12H,6-10H2

Upstream product

• 90633-18-4 4-bromo-1H-piperidine 
• 501-53-1 benzyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 54288-70-9 4-bromopiperidine hydrobromide 
• 95798-23-5 1-(benzyloxycarbonyl)-4-hydroxypiperidine 
• 1972-28-7 diethylazodicarboxylate 

Downstream Products

• 146827-60-3 4-(acetylthio)-1-(benzyloxycarbonyl)piperidine 
• 954412-37-4 benzyl 4-(prop-1-en-2-yl)piperidine-1-carboxylate 
• 66207-23-6 1-benzyloxycarbonyl-1,2,3,6-tetrahydropyridine 
• 3742-91-4 N-(benzyloxycarbonyl)piperidine 
• 1253596-96-1 benzyl 4-(3-phenylpropyl)piperidine-1-carboxylate 
• 1353557-76-2 1-benzyloxycarbonyl-4-[(1E)-2-cyclopropylvinyl]piperidine 
• 1353557-77-3 1-benzyloxycarbonyl-4-(1-phenylvinyl)piperidine 
• 733810-73-6 phenylmethyl 4-phenylhexahydropyridine-1-carboxylate 
• 1417437-42-3 2-(1-(benzyloxycarbonyl)piperidin-4-yl)-6-methylpyridine 1-oxide 
• 1380313-68-7 4-(2-4,4,5,5-tetramethyl-1,3,2-dioxaborolanyl)piperidine-1-carboxylic acid benzyl ester 

Relevant articles and documents

Copper-Catalyzed Reductive Cross-Coupling of Nonactivated Alkyl Tosylates and Mesylates with Alkyl and Aryl Bromides

A copper-catalyzed reductive cross-coupling reaction of nonactivated alkyl tosylates and mesylates with alkyl and aryl bromides was developed. It provides a practical method for efficient and cost-effective construction of aryl-alkyl and alkyl-alkyl C=C bonds with stereocontrol from readily available substrates. When used in an intramolecular fashion, the reaction enables convenient access to various substituted carbo- or heterocycles, such as 2,3-dihydrobenzofuran and benzochromene derivatives.

1-(4-PIPERIDINYL) BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS

Disclosed are histamine H3 antagonists of the formula (I) wherein R1 is benzimidazolone derivative, M1 and M2 are optionally substituted carbon or nitrogen, R2 includes optionally substituted aryl or heteroaryl, and the remaining variables are as defined

Heterocyclic compouds

A compound of the general formula wherein: n is 0 or 1; M1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.